Global Cancer mTOR Inhibitors Market Research Report 2012-2023

1 Market Overview

1.1 Objectives of Research

1.1.1 Definition

1.1.2 Specifications

1.2 Market Segment

1.2.1 by Type

1.2.1.1 Afinitor/Votubia

1.2.1.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor

1.2.1.3 Torisel (Temsirolimus)

1.2.1.4 Evertor andndash

1.2.2 by Application

1.2.2.1 Breast Cancer

1.2.2.2 Hematological Malignancy

1.2.2.3 Neuroendocrine Tumors

1.2.2.4 Hepatocellular Carcinoma

1.2.2.5 Glioblastoma

1.2.3 by Regions

2 Industry Chain

2.1 Industry Chain Structure

2.2 Upstream

2.3 Market

2.3.1 SWOT

2.3.2 Dynamics

3 Environmental Analysis

3.1 Policy

3.2 Economic

3.3 Technology

3.4 Market Entry

4 Market Segmentation by Type

4.1 Market Size

4.1.1 Afinitor/Votubia Market, 2012-2017

4.1.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Market, 2012-2017

4.1.3 Torisel (Temsirolimus) Market, 2012-2017

4.1.4 Evertor andndash Market, 2012-2017

4.2 Market Forecast

4.2.1 Afinitor/Votubia Market Forecast, 2018-2023

4.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Market Forecast, 2018-2023

4.2.3 Torisel (Temsirolimus) Market Forecast, 2018-2023

4.2.4 Evertor andndash Market Forecast, 2018-2023

5 Market Segmentation by Application

5.1 Market Size

5.1.1 Breast Cancer Market, 2012-2017

5.1.2 Hematological Malignancy Market, 2012-2017

5.1.3 Neuroendocrine Tumors Market, 2012-2017

5.1.4 Hepatocellular Carcinoma Market, 2012-2017

5.1.5 Glioblastoma Market, 2012-2017

5.2 Market Forecast

5.2.1 Breast Cancer Market Forecast, 2018-2023

5.2.2 Hematological Malignancy Market Forecast, 2018-2023

5.2.3 Neuroendocrine Tumors Market Forecast, 2018-2023

5.2.4 Hepatocellular Carcinoma Market Forecast, 2018-2023

5.2.5 Glioblastoma Market Forecast, 2018-2023

6 Market Segmentation by Region

6.1 Market Size

6.1.1 Asia-Pacific

6.1.1.1 Asia-Pacific Market, 2012-2017

6.1.1.2 Asia-Pacific Market by Type

6.1.1.3 Asia-Pacific Market by Application

6.1.2 North America

6.1.2.1 North America Market, 2012-2017

6.1.2.2 North America Market by Type

6.1.2.3 North America Market by Application

6.1.3 Europe

6.1.3.1 Europe Market, 2012-2017

6.1.3.2 Europe Market by Type

6.1.3.3 Europe Market by Application

6.1.4 South America

6.1.4.1 South America Market, 2012-2017

6.1.4.2 South America Market by Type

6.1.4.3 South America Market by Application

6.1.5 Middle East & Africa

6.1.5.1 Middle East & Africa Market, 2012-2017

6.1.5.2 Middle East & Africa Market by Type

6.1.5.3 Middle East & Africa Market by Application

6.2 Market Forecast

6.2.1 Asia-Pacific Market Forecast, 2018-2023

6.2.2 North America Market Forecast, 2018-2023

6.2.3 Europe Market Forecast, 2018-2023

6.2.4 South America Market Forecast, 2018-2023

6.2.5 Middle East & Africa Market Forecast, 2018-2023

7 Market Competitive

7.1 Global Market by Vendors

7.2 Market Concentration

7.3 Price & Factors

7.4 Marketing Channel

8 Major Vendors

8.1 Abraxis BioScience

8.1.2 Profile

8.1.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.2 Adimab

8.2.1 Profile

8.2.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.3 Celgene Corporation

8.3.1 Profile

8.3.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.4 Celator Pharmaceuticals

8.4.1 Profile

8.4.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.5 Eli Lilly

8.5.1 Profile

8.5.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.6 Exelixis

8.6.1 Profile

8.6.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.7 GlaxoSmithKline

8.7.1 Profile

8.7.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.8 HEC Pharm

8.8.1 Profile

8.8.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.9 Intellikine

8.9.1 Profile

8.9.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.10 Novartis

8.10.1 Profile

8.10.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.11 Oneness Biotech

8.12 PIQUR Therapeutics

8.13 Semafore Pharmaceuticals

8.14 Takeda

8.15 Wyeth

9 Conclusion

Table Products Segment of Cancer mTOR Inhibitors

Table Afinitor/Votubia Overview

Table Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Overview

Table Torisel (Temsirolimus) Overview

Table Evertor andndash Overview

Table Global Cancer mTOR Inhibitors Market by Type, 2011-2022 (USD Million)

Table Application Segment of Cancer mTOR Inhibitors

Table Breast Cancer Overview

Table Hematological Malignancy Overview

Table Neuroendocrine Tumors Overview

Table Hepatocellular Carcinoma Overview

Table Glioblastoma Overview

Table Global Cancer mTOR Inhibitors Market by Application, 2011-2022 (USD Million)

Table Global Cancer mTOR Inhibitors Market by Region, 2011-2022 (USD Million)

Table Cost of Cancer mTOR Inhibitors

Table Market Dynamics

Table Policy of Cancer mTOR Inhibitors

Table GDP of Major Countries

Table Afinitor/Votubia CAGR by Revenue and Volume, 2012-2017

Table Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor CAGR by Revenue and Volume, 2012-2017

Table Torisel (Temsirolimus) CAGR by Revenue and Volume, 2012-2017

Table Evertor andndash CAGR by Revenue and Volume, 2012-2017

Table Afinitor/Votubia CAGR by Revenue and Volume, 2012-2022

Table Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor CAGR by Revenue and Volume, 2012-2022

Table Torisel (Temsirolimus) CAGR by Revenue and Volume, 2012-2022

Table Evertor andndash CAGR by Revenue and Volume, 2012-2022

Table Breast Cancer CAGR by Revenue and Volume, 2012-2017

Table Hematological Malignancy CAGR by Revenue and Volume, 2012-2017

Table Neuroendocrine Tumors CAGR by Revenue and Volume, 2012-2017

Table Hepatocellular Carcinoma CAGR by Revenue and Volume, 2012-2017

Table Glioblastoma CAGR by Revenue and Volume, 2012-2017